Andarine

Andarine functions as a selective androgen receptor modulator, meaning it binds to androgen receptors with high affinity but exhibits tissue-specific activity. Unlike non-selective anabolic steroids, Andarine preferentially activates receptors in skeletal muscle and bone, promoting protein synthesis and inhibiting catabolism in these tissues. This selectivity is the theoretical basis for its profile, aiming to deliver anabolic benefits while reducing androgenic side effects in other systems. However, research indicates that selectivity is not absolute. At higher doses, the compound may exert effects on other tissues, including the liver and cardiovascular system. The mechanism involves stabilizing the receptor complex to facilitate gene transcription related to muscle growth. It does not suppress the hypothalamic-pituitary-gonadal axis as aggressively as traditional steroids, though some suppression of natural testosterone production is commonly reported by users at standard dosages.

Andarine is predominantly used in cutting and recomposition cycles due to its ability to preserve lean mass during caloric restriction. Athletes and researchers often utilize it to enhance muscle definition and vascularity without the significant water retention seen with other agents. It is rarely used as a standalone bulking agent because its anabolic strength is considered moderate compared to heavier compounds. In recomposition protocols, GTx-007 is frequently stacked with other SARMs or mild anabolic steroids to maximize fat loss while maintaining muscle tone. Users report that it pairs well with compounds like Ostarine or LGD-4033 for balanced results. It is not typically recommended for pure strength gains, as the strength-to-size ratio is not as pronounced as with more potent androgens. The compound is often chosen for its perceived ease of use and lower barrier to entry for those new to selective modulators.

Standard research protocols for Andarine typically range from 25 mg to 50 mg per day. Doses below 25 mg are often considered sub-therapeutic for significant effects, while doses exceeding 50 mg per day are associated with a higher incidence of adverse visual effects. Cycle lengths generally span 8 to 12 weeks, which allows for sufficient time to observe changes in body composition without prolonged exposure. Some users split the daily dose into two administrations to maintain stable blood levels, though once-daily dosing is common. It is crucial to note that bioavailability is not fully established, and individual responses may vary. Post-cycle therapy (PCT) is often recommended after cycles exceeding 8 weeks to support natural testosterone recovery. Intermediate users might start at 25 mg to assess tolerance before increasing to 50 mg. Advanced users may push to 50 mg daily, but this increases the risk profile significantly.

The most distinct side effect of Andarine is visual impairment, specifically a yellow or green tint to vision and difficulty with dark adaptation. This effect is dose-dependent and typically reversible upon cessation, but it can be disorienting and dangerous for activities like driving. Other reported side effects include mild testosterone suppression, which may require PCT support. Hepatotoxicity is a concern with all oral SARMs, and Andarine is no exception; regular blood work monitoring liver enzymes is essential. Users may also experience mild headaches, nausea, or fatigue. It is not recommended for individuals under 21 or those with pre-existing liver or cardiovascular conditions. Because it is a research compound, there are no standardized safety guidelines, and quality control varies between manufacturers. Always source from reputable vendors and verify purity through third-party testing. Discontinue use immediately if severe visual changes or other adverse reactions occur.

Mechanism of action

Andarine acts as a selective androgen receptor modulator, binding to androgen receptors in skeletal muscle and bone to promote anabolic effects while minimizing androgenic activity in other tissues.